Buspirone, fexofenadine, and omeprazole: Quantification of probe drugs and their metabolites in human plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 5, 2011, Pages 1127-1135

  Gor, Parul ^a   Alnouti, Yazen ^a   Reed, Gregory A ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Buspirone; Fexofenadine; Human plasma; Omeprazole; Probe drug cocktail

Indexed keywords

ACETONITRILE; BUSPIRONE; DRUG METABOLITE; FEXOFENADINE; LANSOPRAZOLE; OMEPRAZOLE; OMEPRAZOLE SULFONE;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; ELECTROSPRAY; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

BUSPIRONE; CALIBRATION; CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; HUMANS; MODELS, CHEMICAL; OMEPRAZOLE; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TERFENADINE;

EID: 79956072689     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.03.043     Document Type: Article

References (27)

1. Kivisto K.T., Kroemer H.K. Use of probe drugs as predictors of drug metabolism in humans. J. Clin. Pharmacol. 1997, 37:40S-48S.
2. Frye R.F. Probing the world of cytochrome P450 enzymes. Mol. Interv. 2004, 4:157-162.
3. Zhou H., Tong Z., McLeod J.F. Cocktail approaches and strategies in drug development: valuable tool or flawed science?. J. Clin. Pharmacol. 2004, 44:120-134.
4. Wilkinson G.R. In vivo probes for studying induction and inhibition of cytochrome P450 enzymes in humans. Drug-Drug Interactions 2008, 581-641. Informa Healthcare, New York. A.D. Rodrigues (Ed.).
5. Andersson T., Miners J.O., Veronese M.E., Tassaneeyakul W., Meyer U.A., Birkett D.J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 1993, 36:521-530.
6. Karam W.G., Goldstein J.A., Lasker J.M., Ghanayem B.I. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos. 1996, 24:1081-1087.
7. Sohn D.R., Kobayashi K., Chiba K., Lee K.H., Shin S.G., Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J. Pharmacol. Exp. Ther. 1992, 262:1195-1202.
8. Chang M., Dahl M.L., Tybring G., Gotharson E., Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995, 5:358-363.
9. Gonzalez H.M., Romero E.M., Chavez Tde J., Peregrina A.A., Quezada V., Hoyo-Vadillo C. Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2002, 780:459-465.
10. Gonzalez H.M., Romero E.M., Peregrina A.A., de J.C.T., Escobar-Islas E., Lozano F., Hoyo-Vadillo C. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J. Clin. Pharmacol. 2003, 43:1211-1215.
11. Kivisto K.T., Lamberg T.S., Kantola T., Neuvonen P.J. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. 1997, 62:348-354.
12. Arellano C., Philibert C., Vachoux C., Woodley J., Houin G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J. Pharm. Sci. 2007, 10:26-36.
13. Lilja J.J., Kivisto K.T., Backman J.T., Lamberg T.S., Neuvonen P.J. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin. Pharmacol. Ther. 1998, 64:655-660.
14. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 1999, 27:866-871.
15. Coutant J.E., Westmark P.A., Nardella P.A., Walter S.M., Okerholm R.A. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 1991, 570:139-148.
16. Lamberg T.S., Kivisto K.T., Neuvonen P.J. Concentrations and effects of buspirone are considerably reduced by rifampicin. Br. J. Clin. Pharmacol. 1998, 45:381-385.
17. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31:815-832.
18. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., Lan L.B., Schuetz J.D., Schuetz E.G., Wilkinson G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001, 70:189-199.
19. Hamman M.A., Bruce M.A., Haehner-Daniels B.D., Hall S.D. The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. 2001, 69:114-121.
20. Sakr A., Andheria M. Pharmacokinetics of buspirone extended-release tablets: a single-dose study. J. Clin. Pharmacol. 2001, 41:783-789.
21. Song Q., Naidong W. Analysis of omeprazole and 5-OH omeprazole in human plasma using hydrophilic interaction chromatography with tandem mass spectrometry (HILIC-MS/MS)-eliminating evaporation and reconstitution steps in 96-well liquid/liquid extraction. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2006, 830:135-142.
22. Drescher S., Schaeffeler E., Hitzl M., Hofmann U., Schwab M., Brinkmann U., Eichelbaum M., Fromm M.F. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 2002, 53:526-534.
23. Tybring G., Bottiger Y., Widen J., Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin. Pharmacol. Ther. 1997, 62:129-137.
24. Scott R.J., Palmer J., Lewis I.A., Pleasance S. Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun. Mass Spectrom. 1999, 13:2305-2319.
25. Yin O.Q., Lam S.S., Lo C.M., Chow M.S. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun. Mass Spectrom. 2004, 18:2921-2933.
26. Zhang W., Han F., Guo P., Zhao H., Lin Z.J., Huang M.Q., Bertelsen K., Weng N. Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS-a high throughput approach to evaluate drug-drug interactions. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2010, 878:1169-1177.
27. Videau O., Delaforge M., Levi M., Thevenot E., Gal O., Becquemont L., Beaune P., Benech H. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun. Mass Spectrom. 2010, 24:2407-2419.